Search results
Results from the WOW.Com Content Network
John Francis Crowley (born April 7, 1967) is the President and CEO of the Biotechnology Innovation Organization (BIO), the world’s largest biotechnology advocacy organization. [1] He served as the chairman and CEO of Amicus Therapeutics.
In 2016 Amicus acquired MiaMed which was working on drugs to treat CDKL5 deficiency; Amicus paid $1.8M in cash and around $4.7M in stock, with $83M in biodollars. [ 18 ] After Scott Gottlieb became FDA commissioner in 2017, the CEO of Amicus began lobbying him directly for the FDA to accept the NDA and in February 2018 the FDA accepted it and ...
Whitman is Chief Executive of Colmar Holdings, which provides capital and governance to enterprises committed to the common good. [1] He is a member of the Boards of Directors of two publicly listed companies: Amicus Therapeutics (Nasdaq: FOLD), a global biotech and biopharma company which provides advanced therapies for rare diseases; [2] [3] and Omega Healthcare Investors (NYSE: OHI), a ...
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025 PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at the 21st Annual WORLDSymposium™ 2025 , being ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
He was the co-founder of Amicus Therapeutics, a biopharmaceutical company developing pharmacologic chaperone therapies (Galafold approved 2018 [4]), and served as the Chairman of the Scientific Advisory Committees (SAC) of Synageva BioPharma [5] and Kiniksa Pharmaceuticals.
After having been a director since December 2019, Duggan was appointed as CEO of Summit Therapeutics, a clinical-stage drug development company focused on new mechanism antibiotics, in spring 2020. [40] He is the company's leading shareholder and its CEO. [40] Summit is focused on developing ridinilazole, a potential new treatment for C ...